Stoppel Laura was awarded 16,250 derivative securities of Artiva Biotherapeutics on 2026-09-10. The award equals 100.0% of the resulting derivative-securities holding, giving investors a clear picture of the insider’s post-transaction position and the transaction’s full relationship to that holding.
Key Highlights
- The transaction occurred on 10 September 2026.
- The filing identifies the transaction with SEC transaction code A.
- The award represented about 100.0% of Stoppel Laura’s resulting derivative-securities holding.
Award Recorded Under Transaction Code A
The award was recorded on 10 September 2026 under transaction code A. Stoppel Laura’s post-transaction position was 16,250 derivative securities, matching the amount awarded. Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) is the named company connected with the transaction. Stoppel Laura’s transaction represented about 100.0% of the resulting derivative-securities holding. Transaction code A denotes an award, grant, or other Acquisition from the company.
FAQs
Q: What did Stoppel Laura receive from Artiva Biotherapeutics?
A: Stoppel Laura was awarded 16,250 derivative securities of Artiva Biotherapeutics. The filing identifies the transaction with SEC transaction code A.
Q: What does the Artiva Biotherapeutics insider transaction show?
A: The transaction shows that about 100.0% of Stoppel Laura’s resulting derivative-securities holding was represented by the award. The reported proportion was about 100.0%.
Q: When did Stoppel Laura’s Artiva Biotherapeutics award occur?
A: Stoppel Laura’s award at Artiva Biotherapeutics, Inc. was recorded on 10 September 2026 under transaction code A. Her post-transaction position was 16,250 derivative securities, matching the amount awarded.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.